The Evil Gene backdrop
VERDICT: Disaster
Expert Verified

Is The Evil Gene a Hit or Flop? Official Box Office Record & Profit Analysis

The official verdict is out. With a worldwide gross of $30,000,000.00, The Evil Gene is declared a Disaster.

📊 Box Office Snapshot

Budget$50,000,000.00
Box Office$30,000,000.00
Profit / Loss -$20,000,000.00
Return on Investment (ROI) -40%

* A movie is generally considered a "Hit" if it recovers its budget and marketing costs (approx 2x budget).

📔 Detailed Verdict Analysis

📜 Detailed Financial Report

In the competitive landscape of 2016, The Evil Gene debuted as a Thriller / Horror film with significant commercial expectations. The production path for this project involved significant capital, with a reported budget of approximately $50,000,000.00. In the modern film economy, recovering such an investment requires a multifaceted theatrical strategy spanning domestic and international territories.

📈 Collection Trajectory

The box office journey for The Evil Gene has culminated in a worldwide gross of approximately $30,000,000.00. This figure represents the total theatrical footprint, reflecting a Return on Investment (ROI) of -40%. Despite the hype, the ticket sales faced headwinds, resulting in a total that fell short of the necessary threshold for theatrical profitability.

⚖️ Profitability & Verdict

Analyzing the multiplier effect and market sentiment, The Evil Gene navigated the competitive landscape with an audience reception score of 2.6/10. When weighing the production costs against the global returns, The Evil Gene is effectively categorized as a Disaster. It serves as an analytical benchmark for the complexities of modern theatrical distribution and evolving viewer preferences.

🔍 Comparables

In the context of other Thriller releases, the performance of The Evil Gene will likely influence how studios approach similar projects in the future. Whether through its innovative visual style or its narrative choices, the film's financial footprint remains a key piece of the 2016 box office narrative.